Anti-tumour necrosis factor (TNF) therapies, such as infliximab, adalimumab, certolizumab
pegol and golimumab, have been proven to be effective for the treatment of patients with …

Opinion statement While anti-TNF agents have had a marked impact in the treatment of
inflammatory bowel disease, a significant number of patients lose their response to these …

The antitumour necrosis factor (TNF) medications, adalimumab and infliximab, play an
important role in the management of both Crohn's disease and ulcerative colitis. For those in …

The treatment of IBD with anti-TNF agents has substantially evolved since their first
introduction more than a decade ago. The robust efficacy witnessed in many patients has …

Anti–tumor necrosis factor (TNF) therapy has revolutionized the treatment of inflammatory
bowel disease (IBD). However, up to 30% of patients with IBD show no clinical benefit and …

Introduction: In the last two decades, with the development of biological (anti-TNFα) therapy,
the treatment paradigms for Crohn's disease and ulcerative colitis have evolved, with a …

Background Therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD)
patients receiving anti‐tumour necrosis factor (TNF) agents can help optimise outcomes …

Antitumor necrosis factor α (anti-TNF) agents have dramatically influenced management of
refractory inflammatory bowel disease (IBD). However, not all patients respond to treatment …

Anti-tumor necrosis factor (TNF) therapy is effective for the treatment of the inflammatory
bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC). Nevertheless, up to …

Aliment Pharmacol Ther 2011; 33: 987–995 Summary Background Loss of response to anti‐
TNF agents in Crohn's disease is an emerging clinical problem. Aim To review the causes …